Lipoxygenase Inhibitors
2 drugsAbout Lipoxygenase
Lipoxygenases (LOX) are non-heme iron dioxygenases that oxidize polyunsaturated fatty acids, producing signaling molecules involved in inflammation.
Lipoxygenases are attractive drug targets in immunology due to the involvement of their products in inflammatory pathways; however, there is currently no genetic evidence directly linking them to specific diseases.
Two FDA-approved drugs, COLAZAL and BALSALAZIDE DISODIUM, target lipoxygenases as small molecules for inflammatory bowel disease.
Top Lipoxygenase Drugs
ZYDUS LIFESCIENCES and VALEANT PHARMS INTL are the companies with approved drugs.
The market is not highly competitive, suggesting opportunities for new entrants with novel lipoxygenase inhibitors.
Lipoxygenase Drug Modality Landscape
Modalities
Routes of Administration
Lipoxygenase is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or biologics to differentiate from existing therapies.
Lipoxygenase Drug Approval Timeline (2000 - 2007)
The first drug was approved in 2000, and the most recent in 2007.
The approval timeline shows a stagnant market, indicating potential for innovation in this therapeutic area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Full summary • All drugs • Genetic evidence • Trials • Timeline